Weicong Zhang, Tiansheng Liu, Jialin Li, Jaijeet Singh, Andi Chan, Anam Islam, Alexandra Petrache, Yunan Peng, Kirsten Harvey, Afia B. Ali
{"title":"PNN相关副视蛋白中间神经元突触外δ-GABAA受体的减少与阿尔茨海默病APP和tau小鼠模型的焦虑相关。","authors":"Weicong Zhang, Tiansheng Liu, Jialin Li, Jaijeet Singh, Andi Chan, Anam Islam, Alexandra Petrache, Yunan Peng, Kirsten Harvey, Afia B. Ali","doi":"10.1111/bph.16441","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Alzheimer's disease (AD) is associated with gradual memory loss and anxiety which affects ~75% of AD patients. This study investigated whether AD-associated anxiety correlated with modulation of extrasynaptic δ-subunit-containing GABA<sub>A</sub> receptors (δ-GABA<sub>A</sub>Rs) in experimental mouse models of AD.</p>\n </section>\n \n <section>\n \n <h3> Experimental approach</h3>\n \n <p>We combined behavioural experimental paradigms to measure cognition performance, and anxiety with neuroanatomy and molecular biology, using familial knock-in (KI) mouse models of AD that harbour β-amyloid (Aβ) precursor protein <i>App</i> (<i>App</i><sup><i>NL-F</i></sup>) with or without humanized microtubule-associated protein tau (<i>MAPT</i>), age-matched to wild-type control mice at three different age windows.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p><i>App</i><sup><i>NL-F</i></sup> KI <i>and App</i><sup><i>NL-F</i></sup>/<i>MAPT</i> AD models showed a similar magnitude of cognitive decline and elevated magnitude of anxiety correlated with neuroinflammatory hallmarks, including triggering receptor expressed on myeloid cells 2 (TREM2), reactive astrocytes and activated microglia consistent with accumulation of Aβ, tau and down-regulation of Wnt/β-catenin signalling compared to aged-matched WT controls. In both the CA1 region of the hippocampus and dentate gyrus, there was an age-dependent decline in the expression of δ-GABA<sub>A</sub>Rs selectively expressed in parvalbumin (PV)-expressing interneurons, encapsulated by perineuronal nets (PNNs) in the AD mouse models compared to WT mice.</p>\n \n <p>In vivo positive allosteric modulation of the δ-GABA<sub>A</sub>Rs, using a δ-selective-compound DS2, decreased the level of anxiety in the AD mouse models, which was correlated with reduced hallmarks of neuroinflammation, and ‘normalisation’ of the expression of δ-GABA<sub>A</sub>Rs.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our data show that the δ-GABA<sub>A</sub>Rs could potentially be targeted for alleviating symptoms of anxiety, which would greatly improve the quality of life of AD individuals.</p>\n </section>\n </div>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.16441","citationCount":"0","resultStr":"{\"title\":\"Decreased extrasynaptic δ-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease\",\"authors\":\"Weicong Zhang, Tiansheng Liu, Jialin Li, Jaijeet Singh, Andi Chan, Anam Islam, Alexandra Petrache, Yunan Peng, Kirsten Harvey, Afia B. Ali\",\"doi\":\"10.1111/bph.16441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Alzheimer's disease (AD) is associated with gradual memory loss and anxiety which affects ~75% of AD patients. This study investigated whether AD-associated anxiety correlated with modulation of extrasynaptic δ-subunit-containing GABA<sub>A</sub> receptors (δ-GABA<sub>A</sub>Rs) in experimental mouse models of AD.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Experimental approach</h3>\\n \\n <p>We combined behavioural experimental paradigms to measure cognition performance, and anxiety with neuroanatomy and molecular biology, using familial knock-in (KI) mouse models of AD that harbour β-amyloid (Aβ) precursor protein <i>App</i> (<i>App</i><sup><i>NL-F</i></sup>) with or without humanized microtubule-associated protein tau (<i>MAPT</i>), age-matched to wild-type control mice at three different age windows.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p><i>App</i><sup><i>NL-F</i></sup> KI <i>and App</i><sup><i>NL-F</i></sup>/<i>MAPT</i> AD models showed a similar magnitude of cognitive decline and elevated magnitude of anxiety correlated with neuroinflammatory hallmarks, including triggering receptor expressed on myeloid cells 2 (TREM2), reactive astrocytes and activated microglia consistent with accumulation of Aβ, tau and down-regulation of Wnt/β-catenin signalling compared to aged-matched WT controls. In both the CA1 region of the hippocampus and dentate gyrus, there was an age-dependent decline in the expression of δ-GABA<sub>A</sub>Rs selectively expressed in parvalbumin (PV)-expressing interneurons, encapsulated by perineuronal nets (PNNs) in the AD mouse models compared to WT mice.</p>\\n \\n <p>In vivo positive allosteric modulation of the δ-GABA<sub>A</sub>Rs, using a δ-selective-compound DS2, decreased the level of anxiety in the AD mouse models, which was correlated with reduced hallmarks of neuroinflammation, and ‘normalisation’ of the expression of δ-GABA<sub>A</sub>Rs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Our data show that the δ-GABA<sub>A</sub>Rs could potentially be targeted for alleviating symptoms of anxiety, which would greatly improve the quality of life of AD individuals.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.16441\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bph.16441\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bph.16441","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:阿尔茨海默病(AD)与逐渐丧失记忆和焦虑有关,约 75% 的 AD 患者会因此而焦虑。本研究调查了在 AD 实验小鼠模型中,AD 相关焦虑是否与突触外含 δ 亚基的 GABAA 受体(δ-GABAARs)的调节相关:实验方法:我们使用家族性AD基因敲入(KI)小鼠模型,结合行为学实验范式来测量认知表现和焦虑,并使用神经解剖学和分子生物学方法来测量认知表现和焦虑,该模型含有或不含有人源化微管相关蛋白tau(MAPT)的β-淀粉样蛋白(Aβ)前体蛋白App(AppNL-F),在三个不同的年龄窗口与野生型对照小鼠进行年龄匹配:结果:与年龄匹配的 WT 对照组相比,AppNL-F KI 和 AppNL-F/MAPT AD 模型表现出相似的认知能力下降和焦虑程度升高的神经炎症特征,包括髓系细胞上表达的触发受体 2(TREM2)、反应性星形胶质细胞和活化的小胶质细胞,这与 Aβ、tau 的积累和 Wnt/β-catenin 信号的下调是一致的。在海马CA1区和齿状回,与WT小鼠相比,AD小鼠模型中由神经元周围网(PNNs)包裹的δ-GABAARs选择性地表达在parvalbumin(PV)表达的中间神经元中,其表达量的下降与年龄有关。使用δ选择性化合物DS2对δ-GABAARs进行体内正异位调节,降低了AD小鼠模型的焦虑水平,这与神经炎症特征的减少以及δ-GABAARs表达的 "正常化 "有关:我们的数据表明,δ-GABAARs 有可能成为缓解焦虑症状的靶点,这将大大改善注意力缺失症患者的生活质量。
Decreased extrasynaptic δ-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease
Background
Alzheimer's disease (AD) is associated with gradual memory loss and anxiety which affects ~75% of AD patients. This study investigated whether AD-associated anxiety correlated with modulation of extrasynaptic δ-subunit-containing GABAA receptors (δ-GABAARs) in experimental mouse models of AD.
Experimental approach
We combined behavioural experimental paradigms to measure cognition performance, and anxiety with neuroanatomy and molecular biology, using familial knock-in (KI) mouse models of AD that harbour β-amyloid (Aβ) precursor protein App (AppNL-F) with or without humanized microtubule-associated protein tau (MAPT), age-matched to wild-type control mice at three different age windows.
Results
AppNL-F KI and AppNL-F/MAPT AD models showed a similar magnitude of cognitive decline and elevated magnitude of anxiety correlated with neuroinflammatory hallmarks, including triggering receptor expressed on myeloid cells 2 (TREM2), reactive astrocytes and activated microglia consistent with accumulation of Aβ, tau and down-regulation of Wnt/β-catenin signalling compared to aged-matched WT controls. In both the CA1 region of the hippocampus and dentate gyrus, there was an age-dependent decline in the expression of δ-GABAARs selectively expressed in parvalbumin (PV)-expressing interneurons, encapsulated by perineuronal nets (PNNs) in the AD mouse models compared to WT mice.
In vivo positive allosteric modulation of the δ-GABAARs, using a δ-selective-compound DS2, decreased the level of anxiety in the AD mouse models, which was correlated with reduced hallmarks of neuroinflammation, and ‘normalisation’ of the expression of δ-GABAARs.
Conclusions
Our data show that the δ-GABAARs could potentially be targeted for alleviating symptoms of anxiety, which would greatly improve the quality of life of AD individuals.
期刊介绍:
The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries.
Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues.
In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.